Ignite Creation Date:
2024-05-06 @ 3:42 PM
Last Modification Date:
2024-10-26 @ 1:54 PM
Study NCT ID:
NCT04723472
Status:
SUSPENDED
Last Update Posted:
2022-11-14
First Post:
2021-01-21
Brief Title:
Bismuth Quadruple Therapy With Cefuroxime for Helicobacter Pylori Eradication Treatment
Sponsor:
Shanghai East Hospital
Organization:
Shanghai East Hospital
Study Overview
Official Title:
An Open Randomized Controlled Study of Bismuth Quadruple Therapy With Cefuroxime as Rescue Therapy for Helicobacter Pylori Infection
Status:
SUSPENDED
Status Verified Date:
2022-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Want to modify the study further
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To observe the efficacy of cefuroxime-containing bismuth quadruple regimen in the eradication treatment of Helicobacter pylori and to evaluate whether it can be used as a remedial treatment for Helicobacter pylori after initial or repeated treatment failure
Detailed Description:
Introducing cefuroxime into the remedy treatment of Helicobacter pylori on the one hand the investigators will observe whether cefuroxime can replace tetracycline like amoxicillin on the other hand the investigators will observe whether it can reduce the rate of adverse effects caused by tetracycline and avoid the allergy of penicillin If the experiment is successful it will provide an effective and safe second-line treatment for the majority of patients with failed treatment of Helicobacter pylori
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None